Hiroaki Suga

Hiroaki Suga
Hiroaki Suga
Born	菅裕明; February 21, 1963 (age 61); Okayama, Japan
Education	Okayama University (BSc, MSc); Massachusetts Institute of Technology (PhD);
Known for	RNA-based catalysis
Awards	Wolf Prize (2023);
	Scientific career
Fields	Chemistry
Institutions	Harvard Medical School; University at Buffalo; University of Tokyo;
Thesis	Catalytic antibodies elicited via homologous and heterologous immunization (1994)
Doctoral advisor	Satoru Masamune [jp]

Hiroaki Suga (菅裕明, born February 21, 1963) is a Japanese biochemist and businessman. He is best known for his work on artificial ribozymes (flexizymes) and their application in mRNA display (RaPID, random nonstandard peptide integrated discovery).^[1]^[2]

Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."^[1]

^ ^a ^b Cite error: The named reference wolfprize was invoked but never defined (see the help page).
^ Cite error: The named reference chemviews was invoked but never defined (see the help page).

[wolfprize-1] Cite error: The named reference wolfprize was invoked but never defined (see the help page).

[chemviews-2] Cite error: The named reference chemviews was invoked but never defined (see the help page).

[1]

[2]

Hiroaki Suga
Born	菅裕明 (1963-02-21) February 21, 1963 (age 61) Okayama, Japan
Education	Okayama University (BSc, MSc) Massachusetts Institute of Technology (PhD)
Known for	RNA-based catalysis
Awards	Wolf Prize (2023)

Scientific career
Fields	Chemistry
Institutions	Harvard Medical School University at Buffalo University of Tokyo
Thesis	Catalytic antibodies elicited via homologous and heterologous immunization (1994)
Doctoral advisor	Satoru Masamune [jp]